But no inferences regarding the effect of AC on stage IC2/3 can be made due to the limited size of the non-AC arm.
Furthermore, the administration of adjuvant chemotherapy was found to be associated with a better 5-year OS (OR 4.98, 95% CI 1.12-22.22, P=0.04) in stage IC2/3. For stage IC including 1798 patients, adjuvant chemotherapy revealed a significant survival benefit for 5-year OS (84.5% vs 83.3%, OR 1.44, 95% CI 1.08-1.94, P=0.01). Further subgroup analysis on stage IA/IB suggested that adjuvant chemotherapy did not impact 5-year DFS (OR 0.20, 95% CI 0.01-5.29, P=0.34) or 5-year OS (OR 1.52, 95% CI 0.78-2.98, P=0.22). The 5-year disease-free survival (DFS) and 5-year overall survival (OS) of stage I OCCC were 82.7% and 86.3%, respectively.
Six studies comprising a total of 4553 patients were enrolled in our study, of whom 3320 (72.9%) patients had undergone adjuvant chemotherapy and 1233 (27.1%) had not. Studies that compared the oncological outcomes of adjuvant chemotherapy with observation were included. This systematic review and meta-analysis aimed to assess the impact of adjuvant chemotherapy on survival in patients with stage I OCCC.Įligible studies were screened from PubMed, Web of Science, Embase, and the Cochrane Library up to October 10, 2021. It remains uncertain whether adjuvant chemotherapy improves the prognosis of patients with stage I OCCC. Ovarian clear cell carcinoma (OCCC) is an uncommon subtype of epithelial ovarian carcinoma (EOC) that is often diagnosed at an earlier stage in younger women. Further larger, well-designed prospective studies are warranted to draw firmer conclusions on the intrinsic link between endometriosis and OCCC. Survival differences between the two groups were not significant after stratification analysis for independent prognosticators.ConclusionĮndometriosis was not independently associated with the prognosis of OCCC either in crude analysis or after stratification for stage and RD. The presence of endometriosis did not significantly affect either OS or PFS. There was no significant difference between the two groups regarding age (p-value = 0.2), FIGO stage (p-value = 0.8), residual disease (RD) (p-value = 0.07), adjuvant chemotherapy agent (p-value = 0.4) or chemo-resistance (p-value = 0.9). Clinico-pathological characteristics, progression-free survival (PFS) and overall survival (OS) were collated between the two groups.ResultsForty-six cases of endometriosis-free OCCC (Ef-OCCC) were collated with 48 cases of endometriosis-related OCCC (Er-OCCC). Women were divided into two groups according to the presence of endometriosis. The aim of this study was to ascertain the effect of endometriosis on the prognosis of OCCC.MethodsA retrospective review of the medical records of 94 women diagnosed and treated for OCCC at a tertiary gynaecological cancer centre in the UK, spanning the period 2010–2019. PurposeThe prognostic role of endometriosis amongst women with ovarian clear cell carcinoma (OCCC) remains debatable.
0 kommentar(er)
